Bruker (BRKR): A Textbook Double Whammy
Analysis of a leading scientific instrument maker trading way below fair value
Aurelion Research
Current Price: $36.80 | Market Cap: $5.35B
Executive Summary & Investment Thesis
Bruker Corporation (NASDAQ: BRKR) is a global leader in scientific instruments and analytical solutions used in life sciences, pharmaceuticals, and advanced materials.
Its technologies power the tools behind drug discovery, molecular diagnostics, and semiconductor innovation. Bruker has a clear moat: it dominates highly technical niches, generating about 70% of revenue from markets where it ranks #1.
Today, investors face what we call a textbook double whammy: temporary margin pressure from recent acquisitions and near-term weakness in U.S. research funding.
These short-term headwinds have created a low valuation versus its long-term earnings power. Our management meetings have strengthened our conviction that these issues are temporary, and that Bruker’s fundamentals remain solidly intact.